THE CHALLENGE OF LIPID-MODIFYING THERAPIES IN THE ACHIEVEMENT OF OPTIMAL LDL-C LEVELS IN HIGH AND VERY HIGH CV RISK PATIENTS: STILL AN OPEN QUESTION

被引：0
|
作者：
Rossi, I. [1 ]
D'Ardes, D. [1 ]
Bucciarelli, B. [2 ]
Bianco, F. [3 ]
Troiano, F. [1 ]
Vizzarri, P. [1 ]
Caporale, M. [1 ]
Cipollone, F. [1 ]
Bucci, M. [1 ]
机构：
[1] Univ G dAnnunzio, Med & Aging Sci, Chieti, Italy
[2] Azienda Osped Univ Osped Riuniti, Pediat, Ancona, Italy
[3] Azienda Osped Univ Osped Riuniti, Cardiol, Ancona, Italy
来源：
ATHEROSCLEROSIS | 2022年 / 355卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
EP645
引用
收藏
页码：E306 / E306
页数：1
相关论文
共 47 条
  • [41] Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan
    Teramoto, Tamio
    Uno, Kiyoko
    Miyoshi, Izuru
    Khan, Irfan
    Gorcyca, Katherine
    Sanchez, Robert J.
    Yoshida, Shigeto
    Mawatari, Kazuhiro
    Masaki, Tomoya
    Arai, Hidenori
    Yamashita, Shizuya
    ATHEROSCLEROSIS, 2016, 251 : 248 - 254
  • [42] Contemporary low-density lipoprotein-cholesterol (LDL-C) levels and patient characteristics in 1000 high-risk patients examined in German cardiology practices
    Laufs, U.
    Goss, F.
    Schmid, T.
    Fraass, U.
    Michailov, G.
    EUROPEAN HEART JOURNAL, 2016, 37 : 658 - 658
  • [43] Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United States
    Baum, Seth J.
    Rane, Pallavi B.
    Nunna, Sasikiran
    Habib, Mohdhar
    Philip, Kiran
    Sun, Kainan
    Wang, Xin
    Wade, Rolin L.
    AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2021, 6
  • [44] Extremely high-risk patients with acute coronary syndrome: How "extreme" should lipid-lowering therapy be if the LDL-C target <40 mg/dl is considered?
    Rallidis, Loukianos S.
    Tsamoulis, Donatos
    Leventis, Ioannis
    Kalogeras, Petros
    Delakis, Iosif
    Samiotis, Elefterios
    Kalantzis, Charalampos
    Malkots, Belkis
    Tasoulas, Dimitrios
    Bouratzis, Vasileios
    Eleutheriou, Dimitris
    Dalos, Styliano
    Potoupni, Victoria
    Zervakis, Stelio
    Xygka, Georgia
    Miliotou, Argyro
    Papathanasiou, Konstantinos A.
    Vlachopoulos, Charalambos
    KARDIOLOGIA POLSKA, 2023, 81 (10) : 1012 - 1014
  • [45] Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either &lt;70 mg/dl or ≥50% reduction in high-risk patients: Results from VOYAGER
    Karlson, Bjorn W.
    Nicholls, Stephen J.
    Lundman, Pia
    Palmer, Mike K.
    Barter, Philip J.
    ATHEROSCLEROSIS, 2013, 228 (01) : 265 - 269
  • [46] The new LDL-C target &lt;55 mg/dL is achieved by less than 40% of very high risk patients with familial hypercholesterolaemia despite receiving PCSK9 inhibitors: real world data
    Rallidis, L.
    Vlachopoulos, C.
    Liberopoulos, E.
    Skoumas, I
    Kiouri, E.
    Koutagiar, I
    Anastasiou, G.
    Kosmas, N.
    Tousoulis, D.
    Iliodromitis, E.
    EUROPEAN HEART JOURNAL, 2020, 41 : 2999 - 2999
  • [47] Superior Benefit of Aggressive Lipid-Lowering Therapy for High-Risk Patients Using Statins: the SUBARU Study - More Hypercholesterolemic Patients Achieve Japan Atherosclerosis Society LDL-C Goals with Rosuvastatin Therapy than with Atorvastatin Therapy
    Kurabayashi, Masahiko
    Yamazaki, Tsutornu
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2008, 15 (06) : 314 - 323
12345